Introduction
T-cell immunity can promote or inhibit cancer development and growth (1, 2) . However, the nature of T-cell responses that promote carcinogenesis and cancer growth is less clear. Interleukin-17A (IL-17A), originally identified as cytolytic T-lymphocyte-associated antigen 8, is a T-cell-derived cytokine with homology to Herpesvirus saimiri (3) . It is expressed mainly by activated CD4 + CD45RO + memory T cells (4) . The IL-17 receptor, which is required for IL-17A signaling, is a type I transmembrane protein that is expressed in virtually all cells and tissues, in contrast to the restricted expression of IL-17A, which is confined to T cells (5) . IL-17A is considered a proinflammatory cytokine because it increases IL-6 and IL-8 production by macrophages, fibroblasts, keratinocytes and synovial cells, and nitric oxide production by human osteoarthritic cartilage (6) (7) (8) (9) . IL-17A also induces secretion of IL-1β and tumor necrosis factor-α (TNF-α) by human macrophages and endothelial cells (6) . IL-17A activates nuclear factor-kappa B and activator protein-1 (AP-1) transcription factors, which may explain its proinflammatory properties (10, 11) . Recently, a number of colon carcinogenesis models have suggested a positive association between IL-17A and cancer development (12) . In addition, IL-17A promotes tumorigenicity of human cervical tumors in nude mice (13) . However, the underlying molecular mechanisms and specific signaling pathway of IL-17A remain to be elucidated.
A serine/threonine protein kinase, tumor progression locus 2 (TPL2), also known as Cot, was originally identified as an oncogene by the syrian hamster osaka-kanazawa (SHOK) cell transfection assay (14) and also identified as a target for proviral integration in moloney murine lekemia virus (MoMuLV)-induced rat T-cell lymphomas and mouse mammary tumor virus (MMTV) induced mammary carcinomas (15, 16) . TPL2 belongs to the mitogen-activated protein (MAP) kinase kinase kinase family and can activate extracellular signal-regulated kinase (ERK) 1/2, c-jun N-terminal kinase (JNK) and nuclear factor-kappa B (17, 18) . The TPL2 oncogene is overexpressed in human T-cell neoplasia (19) and in many cancer cells, including breast cancer and lung cancer (20, 21) . The overexpression of TPL2 induces nuclear factor-kappa B as well as AP-1 (22, 23) . It has been suggested that TPL2 regulates neoplastic cellular transformation through transcriptional transactivation. Recently, significant progress has been made in understanding how TPL2 is activated by lipopolysaccharide (LPS) or the proinflammatory cytokines TNF-α and IL-1 (24) . Activation of TPL2 is required for the LPS-induced production of TNF-α in macrophages, and TPL2-deficient mice are protected against experimentally induced inflammatory bowel disease (24) . In addition, TPL2 kinase plays an important role in IL-12 production and T h -cell differentiation (25) . However, it is largely unknown whether TPL2 is also involved in IL-17-induced AP-1 transactivation activity and neoplastic cellular transformation.
Our data provide the first evidence that TPL2 regulates the IL-17A signaling pathway. In this signaling pathway, IL-17A induces TPL2 phosphorylation, which increases the activity of ERK1/2 as well as JNK1/2. Furthermore, IL17A-induced TPL2 phosphorylation affects c-fos and c-jun transcriptional activation, resulting in increased AP-1 activity and neoplastic cellular transformation. These results suggest that TPL2 plays an important role in promoting IL-17A-induced tumorigenesis.
Materials and methods

Reagents and antibodies
Eagle's minimal essential medium, l-glutamine, gentamicin and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA). Cell proliferation enzyme-linked immunosorbent assay and 5-bromo-2′-deoxyuridine (BrdU) (colorimetric) were from Roche Applied Science (Indianapolis, IN). Human IL-17A and IL-17F were obtained from GenScript (Piscataway, NJ). TPL2 kinase inhibitor [TKI; 4-(3-chlor-4-fluorophenylamino)-6-(pyridin-3-ylmethylamino)-3-cyano-1,7-naphthylridine], PD98059 and SP600125 were purchased from Calbiochem-Novabiochem (San Diego, CA). Polyvinylidene difluoride membrane was from Millipore (Bedford, MA). Antibodies against phospho-TPL2, -MEK1/2, -ERK1/2, -JNK1/2, -c-Jun (Ser 63), -STAT3 (Tyr 705), TPL2, MEK1/2, ERK1/2, JNK1/2 and STAT3 were purchased from Cell Signaling Technology (Beverly, MA); antibodies against IL-17A and IL-17R were from R&D systems (Minneapolis, MN); antibodies against c-Jun, proliferating cell nuclear antigen (PCNA), goat anti-mouse IgG horseradish peroxidase (HRP) and goat anti-rabbit IgG HRP were from Santa Cruz Biotechnology (Santa Cruz, CA). The jetPEI cationic polymer transfection Kim et al.
reagent was from Polyplus-transfection (New York, NY). The dual-luciferase reporter assay kit was purchased from Promega (Madison, WI).
Cell culture and transfection JB6 Cl41 mouse epidermal cells and MCF7 human breast cancer cells were cultured in minimal essential medium and Dulbecco's modified Eagle's medium, respectively, supplemented with 5% FBS, at 37°C in humidified air containing 5% CO 2 . The DNA transfection of the cells was performed using a jetPEI cationic polymer transfection reagent (Polyplus-transfection). Mouse IL-17R (accession number: NM_008359), mouse IL-17A (accession number: NM_010552) and TPL2 (accession number: NM_005204) were silenced by transfecting the ON-TARGET plus small interfering RNA (siRNA) SMART pool-specific or non-specific control pool double-stranded RNA oligonucleotides (Dharmacon, Chicago, IL) using Lipofectamine™ 2000 (Invitrogen).
Cell proliferation assay (BrdU incorporation)
Cells were seeded (1 × 10 4 cells per well) in 96-well plates in 100 µl of 5% FBS-minimal essential medium. After 24 h, the cells were treated with/without IL-17A or IL-17F for 48 h, labeled with 10 µl per well BrdU labeling solution and then incubated for 4 h at 37°C in a 5% CO 2 atmosphere. After the media was removed, FixDenat solution was added to each well and incubated at room temperature (RT) for 30 min. After 30 min, FixDenat solution was removed, and anti-BrdU-POD working solution was added to each well and incubated for 90 min at RT. The cells were then washed with washing solution three times, and 100 µl of substrate solution was added in each well and incubated for 30 min. Cell proliferation was estimated by measuring the absorbance at 370 nm.
Immunoblot analysis
The cells were disrupted in RIPA lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 0.2 mM phenylmethylsulfonyl fluoride and 1× protease inhibitors cocktail]. The proteins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes. The membranes were blocked and hybridized with the appropriate primary antibody overnight at 4°C. The protein bands were visualized using chemiluminescence detection kit (Amersham HRP Chemiluminescent Substrates; Amersham Biosciences, Piscataway, NJ) after hybridization with HRP-conjugated secondary antibody from rabbits or mice. A LAS4000-mini (Fujifilm, Tokyo, Japan) was used for chemiluminescence detection.
Reporter gene assays
The reporter gene assay for firefly luciferase activity was performed using lysates from AP-1-, c-jun-, c-fos-luc-or p756-luc-transfected JB6 Cl41 cells. In addition, the reporter gene vector pRL-TK-luciferase plasmid (Promega) was co-transfected into each cell line, and the renilla luciferase activity generated by this vector was used to normalize the results for transfection efficiency. Cell lysates were prepared by first washing the transfected JB6 Cl41 cells once with phosphate-buffered saline at RT. After removing the phosphate-buffered saline completely, passive lysis buffer (Promega) was added, and then cells were incubated at RT for 1 h with gentle shaking. The supernatant fraction was used to measure firefly and renilla luciferase activities. Cell lysates (50 µl) were mixed with 50 µl of luciferase assay II reagent, and firefly luciferase light emission was measured by GloMax®-multi detection system (Promega). Subsequently, 50 µl of renilla luciferase substrate was added in order to normalize the firefly luciferase data. The c-fos-luc promoter (pFos-WT GL3) and c-jun-luc promoter (JC6GL3) constructs were kindly provided by Dr Ron Prywes (Columbia University, New York, NY). The AP-1 luciferase reporter plasmid (−73/+63 collagenase-luciferase) was kindly provided by Dr Dong Zigang (Hormel Institute, University of Minnesota, Austin, MN). The p756-luc promoter was kindly provided by Dr Kang KW (Seoul National University, Seoul, South Korea).
Anchorage-independent cellular transformation assay (soft agar assay)
The effect of IL-17A in the transformation was investigated in JB6 Cl41 cells and MCF7 cells. Briefly, 8 × 10 3 cells were exposed to different doses of IL-17A or IL-17F in 1 ml of 0.3% basal medium Eagle agar containing 10% FBS, 2 mM l-glutamine and 25 µg/ml gentamicin. The cultures were maintained at 37°C in a 5% CO 2 incubator for 14-20 days, and cell colonies were scored using an Axiovert 200 M fluorescence microscope and Axio Vision software (Carl Zeiss, Thornwood, NY).
Chorioallantoic membrane assay
Briefly, fertilized chicken eggs were transferred to an egg incubator and allowed to grow for 10 days. Then, JB6 Cl41 cells (2 × 10 6 ) were placed on the exposed chorioallantoic membrane (CAM), and the eggs were incubated in a humidified incubator at 37°C for 3 days and treated with IL-17A. After 4 days, images were digitally recorded at ×15 magnification with an SZ-61 zoom stereomicroscope (Olympus, Center Valley, PA). Tumor areas were analyzed with ImageJ digital imaging software (downloaded from the NIH website). The tumors were excised, fixed in 10% formalin and embedded in paraffin, and stained with hematoxylin and eosin and anti-PCNA antibody, respectively.
Tumor samples
Among the women who underwent mastectomy for infiltrating duct carcinoma at Chosun University Hospital (Gwangju, Korea) from January 1990 to June 1996, the present study was done in five patients whose paraffin-embedded tissues were relatively well preserved. Informed consent was obtained from all patients, and research protocols were approved by the ethics committee of Chosun University Hospital.
Immunohistochemical staining
All tumors investigated in the study were tested for IL-17A and TPL2. Immunolocalization for each protein was performed using a Polink-2 HRP plus anti-rabbit DAB detection kit (Golden Bridge International, Mukilteo, WA) according to the manufacturer's protocol. Slides were incubated for 1 h with anti-TPL2 antibody (Santa Cruz) and overnight with anti-IL-17A (Santa Cruz) antibody. Instead of the primary antibody, normal goat serum was used in the negative control. Distinct nuclear staining was considered positive immune reactivity.
Statistical analysis
Statistical calculations were carried out with Prism 4 for Macintosh (GraphPad Software, La Jolla, CA). Results are expressed as the mean ± standard error of triplicate measurements of three independent experiments. Student's t-test was used for statistical analyses; P values < 0.05 were considered significant.
Results
IL-17A induces the neoplastic cellular transformation of JB6 Cl41 cells in vitro or in vivo
The mouse skin epidermal JB6 Cl41 cell system is a well-developed model for studying tumor promotion under anchorage-independent growth conditions (26) . To determine whether JB6 Cl41 cells were susceptible to IL-17A-induced cell proliferation and transformation, we first examined the effect of IL-17A on cell proliferation by BrdU incorporation assay. The result showed that treatment with IL-17A significantly and dose-dependently induced the cell proliferation of JB6 Cl41 cells ( Figure 1A) . Next, the cells were subjected to soft agar assays in the absence or presence of IL-17A. The results showed that IL-17A dose-dependently induced the transformation of JB6 Cl41 cells ( Figure 1B) . Furthermore, to determine the tumorigenic effect of IL-17A in vivo, we performed the in vivo CAM assay with JB6 Cl41 cells. Representative images of CAM ( Figure 1C ) and hematoxylin and eosin staining ( Figure 1E ) were shown. For statistical evaluation, tumor section images were digitally recorded, and tumor areas were analyzed ( Figure 1D ). The results showed that IL-17A significantly increased the tumor area compared with untreated control groups. Histologically, the chorioallantoic stroma was distinctly thickened more in IL-17A-treated JB6 Cl41 cells-implanted CAM than only JB6 Cl41 cells-implanted CAM tissues ( Figure 1E ). Additionally, IL-17A-treated JB6 Cl41 cells-implanted CAM showed more of tumor cell invasion ( Figure 1E ). Collectively, these results suggest that IL-17A induces the cellular transformation of JB6 Cl41 cells in vitro and in vivo.
IL-17A induces the phosphorylation of MEKs and JNKs through activation of TPL2
To determine whether IL-17A regulates MAP kinase signaling pathways through TPL2 activation in JB6 Cl41 cells, cells were treated with IL-17A and immunoblotting was performed with specific antibody for phospho-TPL2 (Ser400). The results showed that IL-17A markedly induced the phosphorylation of TPL2 both dose-and timedependently ( Figure 2A) . Next, to examine the effects of knockdown of IL-17 receptor (IL-17R) and IL-17A, cells were transfected with siRNA-IL-17R and -IL-17A, respectively, and treated with or without IL-17A. The results showed that IL-17A-induced phosphorylation of TPL2 were decreased in IL-17R-as well as IL-17A-knockdown cells compared with control cells ( Figure 2B ). Because TPL2 is an upstream kinase of MEK1/2 and JNK1/2, we next assessed whether IL-17A could activate the signaling cascades of MEK-ERK and JNK-c-Jun.
TPL2 mediates IL-17-induced tumorigenesis
The results showed that IL-17A dose-and time-dependently induced the phosphorylation of MEK1/2 and ERK1/2 ( Figure 2C ) as well as JNK1/2 and c-Jun ( Figure 2D ). We also found that treatment with TKI inhibited the IL-17A-induced phosphorylation of MEK1/2, ERK1/2, JNK1/2 and c-Jun ( Figure 2E) . Similarly, PD98059, a specific MEK1/2 inhibitor, and SP600125, a specific JNK inhibitor, inhibited the IL-17A-induced phosphorylation of ERK1/2 and c-Jun, respectively ( Figure 2F and 2G) . Collectively, these results suggest that TPL2 regulates the signaling pathways of MEK-ERK and JNK-cJun induced by IL-17A through the IL-17 receptor in JB6 Cl41 cells.
TPL2 mediates IL-17A-induced AP-1 transactivation and cellular transformation in JB6 Cl41 cells
The AP-1 transcription factor is a complex of homodimers or heterodimers of Jun, Fos, activating transcription factor and musculoaponeurotic fibrosarcoma protein family members that is activated by MAP kinase signaling pathway (27, 28) . To determine the effects of IL-17A on the AP-1 activity, we investigated whether IL-17A might activate the c-fos and c-jun promoter. The transcriptional activity of c-fos and c-jun was significantly increased by treatment with IL-17A in JB6 Cl41 in a dose-dependent manner, respectively ( Figure 3A and 3B). Furthermore, treatment with IL-17A significantly induced the AP-1 transactivation in JB6 Cl41 ( Figure 3C ). To further confirm that AP-1 activation was co-operatively induced by IL-17R-Tpl2 signaling axis, we next assessed IL-17A-induced AP-1 activity in siRNA-IL-17R-, -IL-17A and -TPL2-transfected JB6 Cl41 cells, respectively. As expected, the silencing of IL-17R and IL-17A in JB6 Cl41 cells inhibited the IL-17A-induced AP-1 activity (Figure 3D ), respectively. Also, the Tpl2 silencing almost completely inhibited the AP-1 activity induced by the treatment of IL-17A ( Figure 3E ). In addition, treatment with TKI inhibited the IL-17A-induced AP-1 activity ( Figure 3F ).
To investigate whether TPL2 is indispensible for IL-17A-induced transformation, resulting from increased AP-1 activity, we first examined the effect of IL-17R silencing in JB6 Cl41 cells on the IL-17A-induced transformation. The IL-17R silencing significantly inhibited the IL-17A-induced transformation of JB6 Cl41 cells ( Figure 3G) . Furthermore, the inhibition of TPL2 activity by treatment with TKI significantly and dose-dependently inhibited the IL-17A-induced transformation of JB6 Cl41 cells ( Figure 3H) . Similarly, PD98059, a specific MEK1/2 inhibitor, and SP600125, a specific JNK1/2 inhibitor, significantly inhibited the IL-17A-induced transformation of JB6 Cl41 cells, as measured by soft agar assay ( Figure 3I and 3J) . Taken together, these results strongly support the idea that IL-17A induces the AP-1 activity and neoplastic cellular transformation of JB6 Cl41 cells through IL-17R-TPL2-ERK as well as IL17R-TPL2-JNK signaling pathways.
IL-17F cannot induce TPL2 phosphorylation, AP-1 activity and cell transformation in JB6 Cl41 cells
IL-17F and IL-17A share the strongest amino acid homology, and their coding genes locate adjacent to each other on the chromosome (29) . IL-17F could form homodimers or heterodimers with IL-17A in both human and mice (30) . Therefore, we next examined the effect of IL-17F on the signaling pathway of MEKs as well as JNK. The results showed that IL-17A, but not IL-17F, markedly induced the phosphorylation of TPL2 ( Figure 4A ). We next assessed whether IL-17F could activate the signaling cascades of MEKs-ERKs and JNKs-c-Jun. The results showed that MEK1/2 and ERK1/2 were activated by treatment of IL-17A as well as IL-17F ( Figure 4B ), whereas JNK1/2 and c-Jun were activated by IL-17A, but not by IL-17F ( Figure 4C) . Similarly, the treatment with IL-17F increased c-fos promoter activity dose-dependently ( Figure 4D) , whereas decreased c-jun promoter activity, resulting in no significant differences in AP-1 promoter activity ( Figure 4E and 4F) . Next, we further examined the effects of IL-17F on the cell proliferation and cell transformation of JB6 Cl41 cells using BrdU incorporation assay and soft agar assays. The result showed that treatment with IL-17F had no effect on the cell proliferation and transformation of JB6 Cl41 cells ( Figure 4G and 4H), suggesting that IL-17F may not significantly contribute to tumorigenesis of JB6 Cl41 cells.
IL-17A induces the phosphorylation of STAT3 through activation of TPL2
It has been reported that increased levels of IL-17A stimulate cancer formation via the STAT3 pathway (31) . To determine whether IL-17A regulates STAT3 signaling pathways through TPL2 activation, we first examined the phosphorylation of STAT3 induced by IL-17A in JB6 Cl41 cells. IL-17A markedly induced the phosphorylation of STAT3 both dose-and time-dependently in JB6 Cl41 cells ( Figure 5A ). Furthermore, IL-17A-induced phosphorylation of STAT3 was decreased in IL-17R-as well as IL-17-Aknockdowned JB6 Cl41 cells compared with control cells (Figure 5B and 5C) . Next, to examine the effects of TPL2 inhibition on the IL-17A-induced STAT3 phosphorylation, JB6 Cl41 cells were pretreated with TKI, and then cells were exposed with or without IL-17A. The results showed that TKI dose-dependently inhibited the phosphorylation of STAT3 induced by IL-17A ( Figure 5B ), suggesting that TPL2 positively regulates STAT3 signaling pathway induced by IL-17A. Recent report showed that constitutive activated STAT3 regulates HER2 expression in breast cancer cells (32) . Therefore, we further examined whether inhibition of TPL2 affects the HER2 promoter activity (p756-luciferase promoter) induced by IL-17A in JB6 Cl41 cells. The results showed that IL-17A significantly induced the HER2 promoter activity, whereas TKI significantly decreased the IL-17A-induced HER2 promoter activity dose-dependently ( Figure 5F ). Overall, these results strongly support our hypothesis that TPL2 plays an important role in the IL-17A-induced HER2 expression via activation of STAT3.
TPL2 kinase inhibition and/or IL-17A silencing suppresses tumorigenicity of MCF7 cells
Recently, it was reported that single-nucleotide polymorphisms in IL-17A were associated with the risk of breast cancer (33) . Therefore, we examined the effect of IL-17A on the signaling pathway of MEKs as well as JNKs in MCF7 cells. The results showed that IL-17A markedly induced the phosphorylation of TPL2, resulting in activation of MEK-ERK as well as JNK-c-Jun signaling pathways ( Figure 6A ). We next studied the correlation between TPL2 activity and IL-17A on tumorigenicity of MCF7 cells using BrdU incorporation assay and soft agar assay. The results showed that IL-17A silencing and/or treatment of TKI significantly inhibited the cell proliferation and colony formation of MCF7 cells ( Figure 6B and 6C) . To further confirm the inhibitory effect of TKI on the IL-17A-induced tumorigenesis, in vivo CAM assay with JB6 Cl41 cells was subsequently performed in the absence or presence of IL-17A with/without TKI. Representative Cells were serum starved for 24 h and exposed to the indicated doses of IL-17A for 15 min (left) or exposed to 50 ng/ml IL-17A for the indicated times (right). The proteins in whole cell lysates were determined by immunoblotting analysis using specific antibodies against the corresponding proteins. (E) Cells were serum starved for 24 h, pretreated with the indicated concentrations of TKI for 30 min and then exposed to 50 ng/ml IL-17A for 15 min. Proteins in whole cell lysates were separated by SDS-PAGE and immunoblotted. (F and G) Cells were serum starved for 24 h, pretreated with different concentrations of PD98059 (F) and SP600125 (G) for 1 h, and then exposed to 50 ng/ml IL-17A for 15 min. Proteins in whole cell lysates were separated by SDS-PAGE and immunoblotted. In all of the promoter assays, the firefly luciferase activity was determined in cell lysates and normalized against renilla luciferase activity, and these luciferase activities are expressed relative to control cells, respectively. Columns, mean of triplicate measurements of two experiments; bars, standard deviation. *P < 0.05, compared with control cells (A-E) or only IL-17A-treated cells (F). (G) Cells were transfected with siRNA-control and siRNA-IL-17R, respectively, and subjected to soft agar assays in the absence or presence of 50 ng/ml IL-17A. The representative colonies from three separate experiments were photographed (left), and the colonies were counted under a microscope (right). Columns, mean of triplicate samples; bars, standard deviation. *P < 0.05. (H) Cells were subjected to soft agar assays in the absence or presence of 50 ng/ml IL-17A together with/without treatment of TKI as indicated. The representative colonies from three separate experiments were photographed (left), and the colonies were counted under a microscope (right). Columns, mean of triplicate samples; bars, standard deviation. *P < 0.05. (I and J) Cells were subjected to soft agar assays in the absence or presence of 50 ng/ml IL-17A with/without treatment of PD98059 (I) and SP600125 (J) as indicated. The representative colonies from three separate experiments were photographed (left). The colonies were counted under a microscope (right). Columns, mean of triplicate samples; bars, standard deviation. *P < 0.05. images demonstrate that TKI treatment profoundly reduced the tumor growth induced by IL-17A compared with untreated control group ( Figure 6D, top) . For statistical evaluation, images of sections were digitally recorded, and tumor areas were analyzed. Similar to our in vitro soft agar assay in Figure 3H , the TKI treatment significantly inhibited IL-17A-induced tumor progression of JB6 CL41 cells in CAM of chicken embryos compared with control group (Figure 6D , bottom). Histological examination showed that tumor thickness was reduced in IL-17A-and TKI-co-treated JB6 Cl41 cells-implanted CAM tissues compared with only IL-17A-treated JB6 Cl41 cellsimplanted CAM tissues ( Figure 6E , left-of-bottom). To examine whether the effect of TKI on the IL-17A-induced tumorigenesis is due to inhibition of cell proliferation, the PCNA staining was performed in the CAM tissues using anti-PCNA antibody. The results showed that IL-17A-treated JB6 Cl41 cells-implanted CAM tissues were PCNA-positive, suggesting a high proliferative rate ( Figure 6E,  right-of-center) . However, the numbers of PCNA-positive cells were decreased in the IL-17A-and TKI-co-treated JB6 Cl41 cellsimplanted CAM tissues ( Figure 6E , right-of-bottom), suggesting that TPL2 kinase inhibition suppress tumor progression of JB6 Cl41 cells through inhibition of cell proliferation induced by IL-17A in vivo. To further investigate the pathological relevance between IL-17A and TPL2 expression in breast cancers, we analyzed these two proteins in human breast cancer tissue samples. Immunohistochemical staining showed that both expression of IL-17A (in three of five samples) and TPL2 proteins (in all five samples) were highly upregulated in human breast cancers ( Figure 6F ).
TPL2 mediates IL-17-induced tumorigenesis
Discussion
IL-17A plays an important role in promoting autoimmunity, inflammation and invasion in multiple sclerosis, rheumatoid arthritis and type I diabetes (34) (35) (36) . Despite the role of IL-17A in autoimmunity, relatively little is known about its role in malignancy, and the data 
TPL2 mediates IL-17-induced tumorigenesis
obtained so far are somewhat conflicting. Some reports show that IL-17A supports tumor growth, probably by stimulating angiogenesis of human cervical cancer and murine fibrosarcoma cells when transfected with IL-17 complementary DNA (13, 37) . In contrast, other studies suggest that IL-17 promotes T-cell-mediated tumor rejection (38) . Here, we provide the first direct evidence that IL-17A leads to the activation of TPL2, which plays a critical role in IL-17A-induced AP-1 transactivation activity through the induction of c-fos and c-jun promoter activity. Moreover, the IL-17A-activated TPL2 appears to function upstream of MEK/ERK and JNK/c-Jun, which leads to induction of neoplastic cellular transformation through its downstream AP-1 signaling pathways. Our data indicate that the activation of TPL2 is a major event involved in IL-17A-induced carcinogenesis.
The classical MAP kinase cascade is most commonly considered as a signaling pathway switched on by growth factors and triggered by the Ras-induced activation of the protein kinase Raf. In this pathway, Raf activates MAP kinase kinase-1 (also called MEK1), which then activates two MAP kinase family members, ERK1 and ERK2. However, activation of this pathway by LPS or the proinflammatory cytokines TNF-α and IL-1 does not require Raf, but a distinct MAP kinase kinase kinase 8, known as Cot or TPL2 (39) . The activation of TPL2 is required for the LPS-induced production of TNF-α in macrophages (39) , and TPL2-deficient mice are protected against experimentally induced inflammatory bowel disease (40) . For this reason, TPL2 has become an interesting target for the development of drugs to treat chronic inflammatory disease. Recently, investigations of TPL2 expression in human tumor specimens have shown that TPL2 is overexpressed in various cancer cells (21, 41) . In addition, TPL2 induce cell transformation through upregulation of c-fos transcriptional activity (42) . Previous studies have shown that IL-17A and IL-17F activate MAP kinases including ERK1/2, p38 and JNK1/2 (43). However, little is known about the upstream mediators of IL-17A-induced MAP kinases, including ERK1/2 and JNK1/2. We hypothesized that TPL2 plays a role in IL-17A-mediated neoplastic cellular transformation and tumorigenesis via the activation of ERK1/2 and JNK1/2. Here, we found that IL-17A strongly induces phosphorylation of TPL2 at Ser400, and the knockdown of IL-17R reduces IL-17A-induced TPL2 phosphorylation. These results indicate that TPL2 activation depends on the IL-17A signaling pathway through IL-17 receptor. Moreover, TKI, PD98059 and SP600125, which are TPL2, MEKs and JNKs inhibitors, respectively, strongly suppressed the IL-17A-induced signaling pathways of MEK-ERK and JNK-c-Jun. Overall, these data suggest that TPL2 functions as an upstream mediator of IL-17A-induced MEKs-ERKs and JNKs-cJun signaling pathways.
The MAP kinase signaling pathway plays an important role in activation of AP-1 transcriptional factor, which is implicated in neoplastic transformation (44) . The AP-1 transcription factor is a dimeric complex comprised of members of the Fos, Jun-activating transcription factor and musculoaponeurotic fibrosarcoma protein families (27) . AP-1 is a major transcription factor in the neoplastic transformation of JB6 Cl41 cells induced by various tumor promoters, such as epidermal growth factor and 12-O-tetradecanoylphorbol 13-acetate (45) . Previously, our group reported that the transforming activity of TPL2 results from the co-ordinated activation of chromatin remodeling of histone H3, which ultimately converges on the regulation of c-fos transcriptional activity, followed by AP-1 transcriptional activity (42) . However, little is known about the role of TPL2 in IL-17A-induced AP-1 activity and cellular transformation. This study provides evidence that IL-17A significantly induces c-fos and c-jun promoter activity, resulting in the induction of AP-1 activity in JB6 Cl41 cells. The silencing of IL-17R and TPL2, and also the inhibition of TPL2 activity by TKI, dramatically suppressed the IL-17A-induced AP-1 activity. Similarly, TKI, PD98059 and SP600125, which are TPL2, MEK and JNK inhibitors, respectively, strongly suppressed the IL-17A-induced transformation of JB6 Cl41 cells. IL-17A is the founding member of the proinflammatory IL-17 cytokine family. This cytokine family consists of six members (A-F), with IL-17A and IL-17F sharing the closest amino acid sequence identity of ~50% (46) . IL-17A and IL-17F are homodimeric cytokines produced by the Th17 T-cell lineage and share similar biological activities, including induction of cytokines and chemokines involved in inflammatory responses (43, 47) . IL-17F has been found with a protective role in the development of various cancers, such 
